{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(9)"],"submitter":["O'Keeffe H"],"pubmed_abstract":["<h4>Background</h4>The ASTRAL trial (Angioplasty and Stenting for Renal Artery Lesions) recruited 806 patients between 2000 and 2007. Patients with atherosclerotic renal artery stenosis (RAS) and clinician uncertainty about the benefit of revascularization were randomized 1:1 to medical therapy with or without renal artery stenting. The initial results were presented in 2009 at a median 33.6-month follow-up, with no benefit of revascularization on renal or cardiovascular outcomes. Surviving patients remained under follow-up until the end of 2013, and the long-term results are presented in this study.<h4>Methods</h4>Data were analyzed to assess whether there was a later impact of revascularization on renal function, cardiovascular events, and survival, including a composite outcome of renal"],"journal":["Circulation. Cardiovascular interventions"],"pagination":["e013979"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11404757"],"repository":["biostudies-literature"],"pubmed_title":["Long Term Outcomes After Renal Revascularization for Atherosclerotic Renovascular Disease in the ASTRAL Trial."],"pmcid":["PMC11404757"],"pubmed_authors":["O'Keeffe H","de Bhailis A","Green D","ASTRAL Investigators","Chinnadurai R","Moss J","Wheatley K","Kalra PA"],"additional_accession":[]},"is_claimable":false,"name":"Long Term Outcomes After Renal Revascularization for Atherosclerotic Renovascular Disease in the ASTRAL Trial.","description":"<h4>Background</h4>The ASTRAL trial (Angioplasty and Stenting for Renal Artery Lesions) recruited 806 patients between 2000 and 2007. Patients with atherosclerotic renal artery stenosis (RAS) and clinician uncertainty about the benefit of revascularization were randomized 1:1 to medical therapy with or without renal artery stenting. The initial results were presented in 2009 at a median 33.6-month follow-up, with no benefit of revascularization on renal or cardiovascular outcomes. Surviving patients remained under follow-up until the end of 2013, and the long-term results are presented in this study.<h4>Methods</h4>Data were analyzed to assess whether there was a later impact of revascularization on renal function, cardiovascular events, and survival, including a composite outcome of renal","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2025-04-04T02:53:26.86Z","creation":"2025-04-04T02:53:26.86Z"},"accession":"S-EPMC11404757","cross_references":{"pubmed":["39145377"],"doi":["10.1161/CIRCINTERVENTIONS.123.013979"]}}